DermaVir Family for Personalized Treatment
HIV is a highly variable virus. We found that the therapeutic effectiveness of DermaVir depends on HIV sequence replicating in the patients and the patients' genetic background. To address this challenge we have developed a DermaVir Family, a family of Products containing related HIV-specific antigen sequences characteristic for the different Clades (subtypes) of the virus. To ensure the optimal therapeutic benefit for every patient the treating physician will enter the information on the patient's HIV sequences and genetic background (HLA) into our eMINER software. After analyzing the data the eMINER will select the optimal DermaVir Product from the DermaVir Product Portfolio and also calculate the specific T cell epitopes that will play a role in the immune boosting of the individual patient. The treating physician can then make an educated decision for selecting the optimal Product for his/her patient and could also prescribe the proper monitoring.
The targeted epidemics and our initial Product Portfolio are summarized in the Table below. According to UNAIDS, subtype-B presently represents approximately four million individuals (Europe, North, Central and South America, Caribbean, Australia). Our other Product candidates can provide optimized treatment options for additional 24.7 million HIV-infected individuals (2009 UNAIDS Report and HIV-1 Global Distribution, IAVI report Aug 2003).
|Present DermaVir Product Family||Targeted epidemics||Infected population|
|DermaVir B|| Europe, America, Caribbean, Australia|| 4 million|
|DermaVir C|| Sub-Saharan Africa, South-Asia|| 22.5 million|
|DermaVir BC|| China|| 0.77 million|
|DermaVir BF|| South-America|| 1.4 million|
|DermaVir AB|| East-Europe|| 10,000|